Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Pharmacyclics
December 06, 2016
Ash interview – Seattle’s aspirations versus big pharma’s appetites
October 26, 2016
Buy or build – big pharma’s freshness dilemma
September 07, 2016
How Gilead could go back to basics
August 23, 2016
Who’s next after Medivation?
August 22, 2016
Pfizer pays up
July 12, 2016
Who splashed the cash at the top of the market?
June 06, 2016
Asco 2016 – AbbVie pulls back rova-T curtain
May 23, 2016
In-house projects an ever-thinner slice of sales for big pharma
April 29, 2016
AbbVie caps week of cancer deals with huge Stemcentrx takeout
April 28, 2016
Sanofi’s desperation makes Medivation a must-have asset
April 22, 2016
AbbVie goes preclinical in pursuit of cancer payoff
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
November 10, 2022
Pharma Market Drivers Part Three: Blowin’ in the wind
November 02, 2022
Q3 Round Up: Alive but not kicking report
Editor's Picks
September 28, 2022
Lecanemab can; now the wait for details begins
October 10, 2022
The gloom deepens for biopharma stocks
October 06, 2022
SITC 2022 preview – cytokines and oral checkpoints
September 27, 2022
Big pharma’s key fourth-quarter data
September 21, 2022
TCT 2022 – Otsuka’s renal denervation system shines
